Eptinezumab

Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults[1][2].

[1] Dhillon S. Eptinezumab: First Approval.?Drugs. 2020;80(7):733-739. DOI:10.1007/s40265-020-01300-4
[2] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eptinezumab. 2021 Jul 9. PMID:34292696